Antiphospholipid Antibodies in Women with Recurrent Urinary Tract Infection
Archives of Medical Laboratory Sciences,
Vol. 5 No. 1 (2019),
29 March 2020
https://doi.org/10.22037/amls.v5i1.28894
Abstract
Background: A variety of infections, including acute and recurrent urinary tract infections (UTIs), can trigger production of antiphospholipid antibodies (aPL). These antibodies in women can lead to recurrent pregnancy loss. The aim of this study was to evaluate the prevalence of aPL in recurrent UTI patients.
Materials and Methods: A total 52 subjects who had positive urine culture and 50 healthy individuals as controls were evaluated for presence of lupus anticoagulant (LA), anticardiolipin, anti-β2 GPI(anti-
- Antiphospholipid antibodies
- Recurrent urinary tract infections
- Recurrent pregnancy loss
How to Cite
References
Vojdani, A. A potential link between environmental triggers and autoimmunity. Autoimmune Dis. 2014; 2014: 437231
- Shoenfeld, Y., Blank, M., Lervra, R. et al, Infectious origin of antiphospholipid syndrome. Ann Rheum Dis. 2006; 65: 2–6.
-Cervera R, Asherson RA, Acevedo ML, Gomez- Puerta JA, Espinosa G, De La Red G, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004;63:1312–17.
-Zargar M , Javadi A, Hosseini Z , Shakeri T. Tracking CTX-M gene in Escherichia coli isolates from urinary tract infection in over fifty years women. Bull. Env Pharmacol Life Sci 2015 ;l 4(7):167-171
-Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep 2007;9:212-8.
-Marchetti T, Cohen M, de Moerloose P; Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications. Clin Dev Immunol. 2013;2013:159124.
-Forbes BA. Sahm DF, Weissfeld AS. Bailey and Scott's Diagnostic microbiology, 12th edition, Mosby Elsevier, 2007; 842-55
-Schneider PF, Riley TV. Staphylococcus saprophyticus urinary tract infections: Epidemiological data from Western Australia. Eur J Epidemiol. 1996; 12: 51-4.
-Mandell GL, Bennett JE Dolin R. Principles and practice of infectious diseases.Churchill Livingstone 2005; 881-882.
-Mac Faddin JF. Biochemical tests for identification of medical bacteria. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 2000
Mohsin R, Siddiqui KM. Recurrent urinary tract infections in females. J Pak Med Assoc 2010; 60:55– 9.
Albert X, Huertas I, Pereiro I, Sanfelix J, Gosalbes V, Perrotta C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004; 3:CD001209.
Gopal M, Northington G, Arya L. Clinical symptoms predictive of recurrent urinary tract infections. Am J Obstet Gynecol 2007; 197:74.e1–4.
Foster RT Sr. Uncomplicated urinary tract infections in women. Obstet Gynecol Clin North Am 2008; 35:235–48.
Cervera R, Asherson RA. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics. Immunobiology 2005; 210: 735-41.
Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008; 7: 272-7.
Asheron RA, Ervera R. Antiphospholipid antibodies and infection. Ann Rheum Dis. 2003;62: 388–93.
Misita CP, Moll S. Antiphospholipid antibodies. Circulation 2005;112:e39-44.
Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syndrome and infection. Curr Rheumatol Rep 2001;3: 277-85.
Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90(1):29-37.
Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev. 2010;9: 200–2.
Becarevic M, Ignjatovic S and Majkic-Singh N. Apoptosis. Annexin A5 and Anti- Annexin A5 antibodies in the antiphospholipid syndrome. J Med Biochem. 2013; 32: 89 –95.
Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity. 2005;38: 235–45.
Martinuc Porobic J, Avcin T, Bozic B, et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol. 2005;142: 377–80.
Sebastiani GD, Galeazzi M. Genetic aspects of the antiphospholipid syndrome: HLA associations, Chapter 6. In: Cervera R, Reverter JC, Khamashta M, editors. Antiphospholipid syndrome in systemic autoimmune diseases, Handbook of systemic autoimmune diseases, vol.10. Oxford: Elsevier BC; 2009. p. 81–9.
Hirose N, Williams R, Alberts AR, et al. A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum. 1999;42:1655–61.
Atsumi T, Tsutsumi A, Amengual O, et al. Correlation between beta2-glycoprotein I valine/ leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome. Rheumatology (Oxford). 1999;38:721–3.
Prieto GA, Cabral AR, Zapata-Zuniga M, et al. Valine/valine genotype at position 247 of the beta2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies. Arthritis Rheum. 2003;48:471–4.
Martínez-Flores JA, Serrano M, Morales JM, Serrano A. Antiphospholipid Syndrome and Kidney Involvement: New Insights. Antibodies. 2016; 5(3):17.
Lackner KJ, Müller-Calleja N. Antiphospholipid Antibodies: Their Origin and Development. Antibodies 2016; 5: 15
Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley R E, Zivadinov R. et al. Antiphospholipid antibodies: Paradigm in transition. Journal of Neuroinflammation 2009; 6: 3.
Rohan Willis, Emilio B Gonzalez. Pathogenetic mechanisms of antiphospholipid antibody production in antiphospholipid syndrome. World J Rheumatol. 2015; 5(2): 59-68
- Abstract Viewed: 430 times
- PDF Downloaded: 117 times